Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation:
Lyophilized from a 0.2 µm filtered concentrated solution in 20 mM Tris, pH 8.5, 500 mM NaCl.
Endotoxin:
Less than 1 EU/µg of rHuFGF-13 as determined by LAL method.
Reconstitution:
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.
Stability & Storage:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Usage:
This material is offered by Creative Biomart for research, For research and further manufacturing use only.
background:
Human FGF-13 encoded by the FGF13 gene, belongs to the FGF-11 subfamily which has four members FGF-11 to FGF-14. These four members were initially referred to as fibroblast growth factor homologous factors (FHFs) because they have high sequence identity with the other FGFs but did not activate FGF receptors (FGFRs) and were not generally considered members of the FGF family. FGF-13 plays a crucial role in neuron polarization and migration in the cerebral cortex. In murine FGF-13 RNA was detected in developing central nervous system in cells, and was also found throughout the peripheral nervous system.